Imiglucerase - Sanofi

Drug Profile

Imiglucerase - Sanofi

Alternative Names: Cerecyme; Cerezyme; GZ 437843; Imiglucerase; Selezyme

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Glucosidases
  • Mechanism of Action Glucosylceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gaucher's disease

Most Recent Events

  • 02 Apr 2018 Sanofi plans the ELIKIDS phase III trial for Gaucher's disease type I and type III (In children, In adolescent, Combonation therapy) (IV), in March 2018 (NCT03485677)
  • 27 Oct 2013 Biomarkers information updated
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top